Laurus Labs Limited
LAURUSLABS
Clasificación en acciones
#1737
Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited,... Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited, along with its subsidiaries, operates as a diversified global pharmaceutical company. It focuses on the research, manufacturing, and international distribution of a broad spectrum of medicines and active pharmaceutical ingredients (APIs). The company's API and advanced intermediate offerings cover key therapeutic domains such as anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C. Additionally, Laurus Labs develops and produces oral solid dosage forms targeting ARV, antidiabetic, cardiovascular, PPI, and central nervous system (CNS) conditions. Beyond its proprietary products, the firm extends its expertise through contract development and manufacturing services for other pharmaceutical enterprises. It also supplies specialized ingredients vital for nutraceutical, dietary supplement, and cosmeceutical applications. Furthermore, Laurus Labs is at the forefront of innovation, engineering novel enzymatic solutions for industrial biotechnology, and providing animal-origin-free recombinant proteins and enzymes for biopharmaceutical use, alongside offering a range of business support services within the pharmaceutical industry.
Precio por acción
$22.83
Última sincronización: 2026-10-19
Capitalización bursátil
$12.34B
Cambio (1 día)
0.51%
Cambio (1 año)
117.95%
País
IN
Comercio Laurus Labs Limited (LAURUSLABS)
Categoría
Healthcare
Ganancias de Laurus Labs Limited (LAURUSLABS)
Ganancias en Jun 2026 TTM: $158.77M
Secondo gli ultimi rapporti finanziari di Laurus Labs Limited, gli utili attuali della società sono $158.77M. Nel 2024, la società ha registrato un utile di $27.63M, una disminución en comparación con agli utili del 2023, che erano di $134.55M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Laurus Labs Limited desde 2013 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $158.77M | 178.14% |
| 2025 | $57.08M | 106.57% |
| 2024 | $27.63M | -79.46% |
| 2023 | $134.55M | -5.75% |
| 2022 | $142.76M | -19.68% |
| 2021 | $177.74M | 356.04% |
| 2020 | $38.97M | 126.00% |
| 2019 | $17.25M | -52.71% |
| 2018 | $36.46M | 0.99% |
| 2017 | $36.11M | 41.84% |
| 2016 | $25.45M | 137.71% |
| 2015 | $10.71M | -3.94% |
| 2014 | $11.15M | -29.65% |
| 2013 | $15.85M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 1,011.36% |
IN
|
